MedWatch

Eli Lilly considers copying Novo Nordisk's semaglutide branding strategy

Novo Nordisk branded the GLP-1 analog, semaglutide, under different names for respective treatments of obesity and diabetes. Now, Eli Lilly is chewing over a similar move for tirzepatide.

Photo: Novo Nordisk & Ritzau Scanpix/Reuters/Vincent Kessler

Novo Nordisk has a history of marketing drugs under different names for treatments of obesity and diabetes, respectively. Novo Nordisk's biggest competitor, Eli Lilly, is now pondering a similar move, writes industry media Fiercepharma.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Ambu credits MDR milestone to fastidiousness

All of Medtech firm Ambu’s products already live up to the new EU rules for medical devices, something the firm attributes to a good sense of how much effort living up to the new legislation would require.

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs